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Previewsachieve antitumor effects while mini-
mizing feedback activation of the parallel
pathway? (2) Do our preclinical systems,
where drugs are often tested in vitro for
short periods of time, provide a reliable
measure of antitumor effect when feed-
back activation occurs on this timescale?
Along with the recent genetic evidence
from tumors acquiring resistance to
BYL719 (Juric et al., 2014), the findings
of Schwartz et al. (2015) and Costa et al.
(2015) underscore the fact that tumors
can and will maintain PI3K activation
through a variety of mechanisms in the
face of pharmacologic inhibitors. Our
ability to devise the right combinations of
PI3K isoform inhibitors, or to select the
right subgroup of patientswho can benefitfrom these agents without suffering intol-
erable toxicities, will determine the ulti-
mate clinical impact of this class of drugs.
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In this issue of Cancer Cell, Wong and colleagues describe a novel approach of increasing the number
of functional blood vessels in tumors using a low-dose therapy regimen of Cilengtide and Verapamil.
This method enhanced Gemcitabine delivery, uptake, and metabolism within tumor cells to reduce tumor
growth and progression.The development of new blood vessels
from preexisting vessels is a multifaceted
process known as angiogenesis and a
well-established ‘‘hallmark of cancer’’.
The wealth of proangiogenic molecules
produced by tumor and stroma cells
induces angiogenesis, remodelling of the
vasculature, and recruitment of many
types of lymphoid and myeloid cells as
well as endothelial progenitors. The tumor
vasculature thus differs markedly from
normal vessels, is a key route for metas-
tasis, and is essential for nutrient and
metabolite exchange.
The concept of controlling metastatic
tumors by targeting tumor blood supply
was first proposed in the early 1970s,
and, since then, many drugs targetingblood vessels have been developed
(Figure 1); most specifically inhibit
vascular endothelial growth factor (VEGF)
A function, a major proangiogenic mole-
cule in cancer (Bridges and Harris, 2011).
They have, in several tumor types, a major
therapeutic role, in others a more ancillary
effect. Antiangiogenic therapy has
increased progression-free survival of pa-
tients with many cancers, but resistance
results in antiangiogenic therapy having
little impact on overall survival.
During antiangiogenic treatment (Fig-
ure 1A), a temporary window of opportu-
nity occurs when therapy re-balances
the pro- and antiangiogenic signals to
the point that vessels become more
‘‘natural’’ with improved blood flow intumor regions previously poorly perfused
being observed, referred to as tumor
vasculature normalization (Jain, 2014).
Increased chemotherapy delivery to the
tumor occurs during this short time frame
with improved drug uptake and reduced
side effects observed (Batchelor et al.,
2013). However, the duration of vascular
normalization is time- and dose-depen-
dent, and the onset varies between
patients.
Another mechanism targeting tumor
vasculature is the development of
vascular-disrupting agents that induce
endothelial cell death by disrupting their
cytoskeleton and adhesion to matrix and
activating local coagulation (Figure 1B).
Thus vascular-disrupting agents result27, January 12, 2015 ª2015 Elsevier Inc. 7
Figure 1. Tumor Growth Is Dependent on Nutrient and Oxygen Supply
New blood vessels are formed in a process known as angiogenesis. However, tumor vasculature is
abnormal due to the high abundance of proangiogenic molecules. Different approaches have been taken
to target the tumor blood supply to ultimately block tumor growth and progression.
(A) Antiangiogenic therapy has been developed to specifically block the actions of proangiogenic mole-
cules. (a) As a result of removing the chronic presence of proangiogenic molecules, the vasculature be-
comesmore ‘‘normal like’’ with increased blood flow to regions of the tumor. (b) However, disrupted blood
flow to regions of the tumor occurs as therapy continues, generating hypoxic regions within the tumor.
(B) Vascular disrupting agents target existing blood vessel cells, leading to cell death, and disrupting
the structure and stability of blood vessels and ultimately decreasing blood flow and increasing hypoxic
zones within the tumor. Necrosis is more central, and peripheral blood vessels from normal tissues can
maintain a vascular rim.
(C) In contrast, vascular promoting therapy promotes new and more functional blood vessels, improving
blood supply and perfusion of the tumor and reducing hypoxia within tumors.
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Previewsin vasculature collapse and starvation of
oxygen and nutrients from the tumor.
However, toxicity needs to be reduced
from agents currently under development
before further pursuit.
Many factors contribute to increased
tumor aggression and therapy resistance
following blood vessel-targeting treat-
ment (Bridges and Harris, 2011). Proan-
giogenic molecules are mainly released
by tumor cells found within low-oxygen
(hypoxic) regions within tumors (Se-
menza, 2014). The newly-formed tumor
blood vessels form a chaotic, leaky, and
poorly functional vasculature, reinforcing
a hypoxic environment within the tumors.8 Cancer Cell 27, January 12, 2015 ª2015 ElTumor antiangiogenic therapy increases
hypoxia further (Franco et al., 2006). Hyp-
oxia is, however, associated with poor
patient prognosis and resistance to
chemotherapy (Rebucci and Michiels,
2013). Increased hypoxia promotes tumor
selection of more aggressive tumor cells
better adapted to survive and proliferate
under stressful oxygen-deficient growing
conditions.
The general nature of the proangio-
genic environment within the tumor re-
sults in leaky blood vessels with poor
blood flow in multiple areas in the tumor.
This results in reduced chemotherapy de-
livery and efficacy with more tumor cellssevier Inc.being ‘‘shielded’’ from exposure to treat-
ment. Areas of necrosis and intermittent
hypoxia further compound the problem
of drug delivery, and the reduction of
vessels’ angiogenesis following therapy
can further restrict chemotherapy delivery
(Saggar et al., 2013).
A new approach that addressesmost of
these challenges is reported in this issue
of Cancer Cell (Wong et al., 2015). They
have developed ‘‘vascular promotion
therapy’’ as a means to improve efficacy,
a distinct approach from those of
antiangiogenesis and vascular normaliza-
tion (Figure 1C). The authors used a
low-dosage schedule with vasculature-
affecting agents Cilengitide and Verap-
amil in combination with the chemothera-
peutic agents Gemcitabine or Cisplatin to
target lung and pancreatic ductal adeno-
carcinoma tumor growth. Cilengitide, a
selective inhibitor of av integrins, leading
to inhibition of the FAK/src/AKT pathway
resulting in cell death (apoptosis) in endo-
thelial cells, was originally developed
as an antiangiogenic agent. Cilengitide
failed in clinical trials for the treatment of
glioblastoma when administered in high
doses; however, a proangiogenic effect
with the enhancement of tumor angiogen-
esis was observed following low dosing
of Cilengitide (Reynolds et al., 2009).
Verapamil, a calcium channel blocker,
increased vessel dilation and blood flow
in tumors by relaxing blood vessel mus-
cles; this has been shown to increase
chemotherapeutic efficacy of agents
such as Gemcitabine.
The authors initially assessed Cilengi-
tide, Varapamil in combination with Gem-
citabine in tumors grown subcutaneously,
under the skin, in vivo in various schedules
mimicking human dosing regimens. Tu-
mor progression was initially assessed by
injecting cancer cells into the tail vein of
mice, and tumor cells were allowed to
settle and grow in various metatatic loca-
tionsbefore treatment.Moreclinically rele-
vant and complex in vivo models where
cancer cells were grown orthotopically in
the pancreas, in the site of the primary tu-
mor that the cells were derived from, and a
spontaneous,naturally formed,pancreatic
cancer model were also used. Imaging
techniques, blood-flow, tumor perfusion,
and total blood volume within the tumors
were employed to fully assess the
outcome of therapy on tumor blood
supply. Flow cytometry and CT scans
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Previewsexamined markers and drug concentra-
tions in the organs, tumors, and blood
levels. Examining changes in marker
expression allowed the magnitude of
hypoxia to be scored.
The data reported by Wong et al.
(2015) indicate that co-administration of
Cilengitide and Verapamil increased tu-
mor angiogenesis, yet the vessels that
formed were more functional and less
leaky, resulting in improved blood flow.
The vascular promotion strategy was
effective in both highly and poorly vascu-
larized tumors. Crucially, the degree
of hypoxia within tumors was reduced
following vascular promotion. Tumor
growth and progression was reduced,
even after cessation of treatment, leading
to an extension in survival in in vivo
models.
Additionally, delivery and uptake of
the drug Gemcitabine improved, with
reduced side effects. Gemcitabine uptake
into cells is regulated by equilibrative
nucleoside transporters (ENT) 1 and 2,
and concentrative nucleoside transporter
3 (CNT3) (Farrell et al., 2009). Gemcitabine
is metabolized by rate-limiting metabo-
lizing enzymes such as deoxyxytidine
kinase (DCK). The authors demonstrate
that ENT1 and 2 expression is downregu-
lated in tumor cells under hypoxic condi-
tions and ENT1 and 2 expression was
significantly elevated following vascular-
promoting therapy. CNT3 was also upre-
gulated following Cilengitide treatment,
which mediates the unidirectional flow of
the drug into the cells, thereby increasing
the efficacy of Gemcitabine. Cilengitide
also increased DCK expression. As aconsequence of the ‘‘vascular promotion’’
therapy, an increase in Gemcitabine up-
take by ENT1 and 2, and a decreased
efflux of the drug due to CNT3 led to the
enhanced expression and saturation of
DCK, thus increasing the potency of
Gemcitabine. Wong et al. (2015) also
demonstrated that Cisplatin efficacy
improved following vascular promotion
therapy. However, this was not due to
the influence on the uptake of Cisplatin,
but rather reflected the improved delivery
by blood vessels to tumor regions previ-
ously poorly perfused.
This study provides key evidence that
vascular promotion therapy can increase
chemotherapy delivery to tumors as well
as enhance drug uptake and reduce side
effects. These data thereby challenge
the negative concept that targeting tumor
vasculature ultimately leads to aggressive
tumors as a consequence of increasing
tumor hypoxia, because vascular promo-
tion therapy improves blood flow and
reduces tumor growth and progression.
Future studies should establish if vascular
promoting therapy improves response to
radiation, which is dependent on oxygen
levels, and also whether it can facilitate
other approaches to cancer treatment
by improving vascular access, such as
monoclonal antibodies and nanoparticles
(Neijzen et al., 2014).
Key issues for the clinic relate to the
heterogeneity within different tumor types
and within a tumor, variation between pa-
tients, safety in the presence of vascular
disease, and if vascular promoting ther-
apy will be beneficial in metastatic dis-
ease and in different organs.Cancer CellACKNOWLEDGMENTS
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